The role of UFT in combined-modality therapy

Charles Blanke, Ming Teng, Hak Choy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Fluorinated pyrimidines have long been used as radiosensitizers in combined-modality therapy for solid tumors. Nonetheless, the most commonly used drug, 5-fluorouracil (5-FU), is inconvenient to administer, particularly when given by continuous intravenous infusion. Continuous infusion 5-FU does offer a survival advantage over bolus in the treatment of large bowel tumors. This holds true regardless of whether radiation therapy is concomitantly given. UFT, a combination of uracil and tegafur (in a molar ratio of 4:1), is an attractive alternative. Trials to date suggest at least chemotherapeutic equivalence compared to 5-fluorouracil, and UFT is much simpler to administer. UFT is administered orally and can safely be combined with oral leucovorin. There is profound scientific rationale for using UFT with radiation therapy, and early trials in gastrointestinal malignancies demonstrate the safety and efficacy of the combination. Further studies will determine the optimal timing and uses for concomitant UFT and radiation therapy.

Original languageEnglish (US)
Pages (from-to)47-54
Number of pages8
JournalOncology
Volume13
Issue number10 SUPPL. 5
StatePublished - 1999

Fingerprint

Combined Modality Therapy
Fluorouracil
Radiotherapy
Tegafur
Neoplasms
Pyrimidines
Uracil
Leucovorin
Intravenous Infusions
Safety
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Blanke, C., Teng, M., & Choy, H. (1999). The role of UFT in combined-modality therapy. Oncology, 13(10 SUPPL. 5), 47-54.

The role of UFT in combined-modality therapy. / Blanke, Charles; Teng, Ming; Choy, Hak.

In: Oncology, Vol. 13, No. 10 SUPPL. 5, 1999, p. 47-54.

Research output: Contribution to journalArticle

Blanke, C, Teng, M & Choy, H 1999, 'The role of UFT in combined-modality therapy', Oncology, vol. 13, no. 10 SUPPL. 5, pp. 47-54.
Blanke C, Teng M, Choy H. The role of UFT in combined-modality therapy. Oncology. 1999;13(10 SUPPL. 5):47-54.
Blanke, Charles ; Teng, Ming ; Choy, Hak. / The role of UFT in combined-modality therapy. In: Oncology. 1999 ; Vol. 13, No. 10 SUPPL. 5. pp. 47-54.
@article{ac0aee48cab44dceb010407ffd10433c,
title = "The role of UFT in combined-modality therapy",
abstract = "Fluorinated pyrimidines have long been used as radiosensitizers in combined-modality therapy for solid tumors. Nonetheless, the most commonly used drug, 5-fluorouracil (5-FU), is inconvenient to administer, particularly when given by continuous intravenous infusion. Continuous infusion 5-FU does offer a survival advantage over bolus in the treatment of large bowel tumors. This holds true regardless of whether radiation therapy is concomitantly given. UFT, a combination of uracil and tegafur (in a molar ratio of 4:1), is an attractive alternative. Trials to date suggest at least chemotherapeutic equivalence compared to 5-fluorouracil, and UFT is much simpler to administer. UFT is administered orally and can safely be combined with oral leucovorin. There is profound scientific rationale for using UFT with radiation therapy, and early trials in gastrointestinal malignancies demonstrate the safety and efficacy of the combination. Further studies will determine the optimal timing and uses for concomitant UFT and radiation therapy.",
author = "Charles Blanke and Ming Teng and Hak Choy",
year = "1999",
language = "English (US)",
volume = "13",
pages = "47--54",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "10 SUPPL. 5",

}

TY - JOUR

T1 - The role of UFT in combined-modality therapy

AU - Blanke, Charles

AU - Teng, Ming

AU - Choy, Hak

PY - 1999

Y1 - 1999

N2 - Fluorinated pyrimidines have long been used as radiosensitizers in combined-modality therapy for solid tumors. Nonetheless, the most commonly used drug, 5-fluorouracil (5-FU), is inconvenient to administer, particularly when given by continuous intravenous infusion. Continuous infusion 5-FU does offer a survival advantage over bolus in the treatment of large bowel tumors. This holds true regardless of whether radiation therapy is concomitantly given. UFT, a combination of uracil and tegafur (in a molar ratio of 4:1), is an attractive alternative. Trials to date suggest at least chemotherapeutic equivalence compared to 5-fluorouracil, and UFT is much simpler to administer. UFT is administered orally and can safely be combined with oral leucovorin. There is profound scientific rationale for using UFT with radiation therapy, and early trials in gastrointestinal malignancies demonstrate the safety and efficacy of the combination. Further studies will determine the optimal timing and uses for concomitant UFT and radiation therapy.

AB - Fluorinated pyrimidines have long been used as radiosensitizers in combined-modality therapy for solid tumors. Nonetheless, the most commonly used drug, 5-fluorouracil (5-FU), is inconvenient to administer, particularly when given by continuous intravenous infusion. Continuous infusion 5-FU does offer a survival advantage over bolus in the treatment of large bowel tumors. This holds true regardless of whether radiation therapy is concomitantly given. UFT, a combination of uracil and tegafur (in a molar ratio of 4:1), is an attractive alternative. Trials to date suggest at least chemotherapeutic equivalence compared to 5-fluorouracil, and UFT is much simpler to administer. UFT is administered orally and can safely be combined with oral leucovorin. There is profound scientific rationale for using UFT with radiation therapy, and early trials in gastrointestinal malignancies demonstrate the safety and efficacy of the combination. Further studies will determine the optimal timing and uses for concomitant UFT and radiation therapy.

UR - http://www.scopus.com/inward/record.url?scp=0033212195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033212195&partnerID=8YFLogxK

M3 - Article

C2 - 10550826

AN - SCOPUS:0033212195

VL - 13

SP - 47

EP - 54

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

SN - 0890-9091

IS - 10 SUPPL. 5

ER -